Scinopharm Taiwan, Ltd.TWSE: 1789

Board of Directors approved the company's consolidated financial report of Q2, 2022

· Issued by ScinoPharm Taiwan, Ltd.
Close
Today's Information

Provided by: ScinoPharm Taiwan, Ltd.
SEQ_NO 1 Date of announcement 2022/08/05 Time of announcement 17:00:21
Subject
 Board of Directors approved the company's
consolidated financial report of Q2, 2022
Date of events 2022/08/05 To which item it meets paragraph 31
Statement
1.Date of submission to the board of directors or approval by the board of
 directors:2022/08/05
2.Date of approval by the audit committee:2022/08/03
3.Start and end dates of financial reports or annual self-assessed financial
 information of the reporting period (XXXX/XX/XX~XXXX/XX/XX):
 2022/01/01~2022/06/30
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):1,543,477
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):643,413
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):222,955
7.Profit (loss) before tax accumulated from 1/1 to end of the period
 (thousand NTD):237,506
8.Profit (loss) accumulated from 1/1 to end of the period
 (thousand NTD):191,081
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):191,081
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):0.24
11.Total assets end of the period (thousand NTD):12,035,540
12.Total liabilities end of the period
(thousand NTD):1,652,788
13.Equity attributable to owners of parent end of the
period (thousand NTD):10,382,752
14.Any other matters that need to be specified:None

Company analysis

Earlier from Scinopharm Taiwan

All Scinopharm Taiwan news releases